TAIPEI, TAIWAN – Syncore Biotechnology Co. Ltd. (subsidiary of Taipei-based Sinpharm Pharmaceutical Group) received approval from the FDA for its solid tumor oncology agent SB01 to begin a phase II trial for head and neck cancer.
TAIPEI, TAIWAN – Syncore Biotechnology Co. Ltd. (subsidiary of Taipei-based Sinpharm Pharmaceutical Group) received approval from the FDA for its solid tumor oncology agent SB01 to begin a phase II trial for head and neck cancer.
TAIPEI, Taiwan – As the momentum surrounding high-growth Asian markets seemingly slows, the standing of Taiwan as an innovation and financing center for biotech interests is still strong, at least on the basis of regional comparison. But while public capital markets are vibrant and local valuations high, big international investors remain largely elusive. So say speakers at the Biologics World Taiwan 2015 conference.
TAIPEI, Taiwan – As the momentum surrounding high-growth Asian markets seemingly slows, the standing of Taiwan as an innovation and financing center for biotech interests is still strong, at least on the basis of regional comparison.
TAIPEI, Taiwan – Biopharmaceutical companies, both in the novel drug and biosimilar spaces, are facing long waits for investigational new drug application (IND) approval in China from the CFDA, delays that are slowly stifling the industry. That's according to panelists at a discussion on Taiwan-China partnership issues that took place at the recently concluded Biologics World Taiwan 2015 conference.
TAIPEI, Taiwan – Biopharmaceutical companies, both in the novel drug and biosimilar spaces, are facing long waits for investigational new drug application (IND) approval in China from the CFDA, delays that are slowly stifling the industry.
TAIPEI, Taiwan – Twi Biotechnology Inc., the drug development arm of Taipei, Taiwan-headquartered generics firm Twi Pharmaceutical Inc., recently received orphan drug designation from the FDA for the use of its AC-201 drug candidate to topically treat epidermolysis bullosa (EB). With that new indication, AC-201 is currently under development by Twi in three tracks: type 2 diabetes, gout and now for EB, a debilitating skin condition.
TAIPEI, Taiwan – Twi Biotechnology Inc., the drug development arm of Taipei, Taiwan-headquartered generics firm Twi Pharmaceutical Inc., recently received orphan drug designation from the FDA for the use of its AC-201 drug candidate to topically treat epidermolysis bullosa (EB).
TAIPEI, Taiwan – Oncology-focused Aslan Pharmaceuticals Pte. Ltd. has started dosing the first patients in a safety study of its lead compound ASLAN001, a small-molecule, oral pan-HER inhibitor for the treatment of solid tumors.
TAIPEI, Taiwan – Oncology-focused Aslan Pharmaceuticals Pte. Ltd. has started dosing the first patients in a safety study of its lead compound ASLAN001, a small-molecule, oral pan-HER inhibitor for the treatment of solid tumors.
